Deutsche Bank analyst Emmanuel Papadakis lowered the firm’s price target on Sanofi (SNY) to EUR 90 from EUR 100 and keeps a Hold rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- Sanofi’s Tolebrutinib Study: A Step Forward in Multiple Sclerosis Treatment
- Sanofi’s SAR443579 Study Terminated: Implications for Investors
- Sanofi’s New Study on Teplizumab: A Potential Game-Changer for Type 1 Diabetes in Japan
- Sanofi’s New Study on Lunsekimig: A Potential Game-Changer for Asthma Treatment
- Sanofi’s Teplizumab Study: A Potential Game-Changer for Type 1 Diabetes Treatment